This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

Early Bird pricing expires in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
3 days in-person. 3 days virtually.
March 20–22, 2023 | Basel, SwitzerlandMarch 28–30, 2023 | Digital

Ablevia biotech GmbH

Profile

Austria

ABLEVIA biotech is owner of the SADC-platform technology for the selective depletion of disease-causing and neutralizing antibodies. SADCs are first-in-class, infusible therapeutics, a flexible technology readily adaptable to several disease- and ADA-indications including unmet clinical needs. This technology solves critical issues in a wide array of therapeutic contexts, such as drug inhibition, autoimmune diseases, organ transplantation, gene therapy.

Presenter: Oskar Smrzka, Founder and Inventor, Ablevia biotech GmbH